- REGENXBIO is a biotechnology company specializing in gene therapy, focusing on developing one-time treatments for rare and retinal diseases, with a strong market position highlighted by its advanced late-stage pipeline.
- In 2025, REGENXBIO reported significant progress, including robust patient enrollment in its RGX-202 trial for Duchenne muscular dystrophy, with topline pivotal results expected in early Q2 2026.
- The company has established strategic partnerships with Nippon Shinyaku for RGX-121 and AbbVie for surabgene lomparvovec (ABBV-RGX-314), enhancing its capabilities in treating MPS II, MPS I, and retinal diseases.
- REGENXBIO's ideal buyers are healthcare providers and payers looking for innovative gene therapies that address significant unmet needs in rare diseases, making it a timely opportunity for sales teams to engage as pivotal data readouts are imminent in 2026.
Engineering is the largest group at 85 employees, accounting for about one-quarter of the total workforce and underscoring the company’s focus on vector design and process development. Clinical and laboratory work is represented by 60 professionals in Healthcare roles, while Operations (47) and Business Management (34) provide manufacturing and administrative support. Finance & Administration (14), Quality (13), Marketing & Product (11), Program & Project Management (11), and Information Technology (10) round out the functional areas, with 24 employees categorized as Other specialized roles. Overall departmental data suggests a strong emphasis on R&D and technical execution balanced by the infrastructure needed to advance gene therapy programs.
REGENXBIO’s talent footprint is heavily rooted in the Maryland/DC biotechnology corridor. Washington, DC hosts 68 employees and nearby Rockville, MD—home to the company’s headquarters and manufacturing facility—employs 46. Additional clusters are found in Gaithersburg (18), Germantown (14), Frederick (9), Silver Spring (6), Bethesda (5), Laurel (5), and Baltimore (5), creating a network of sites within commuting distance of one another. A further 133 employees are listed under Other locations, indicating a blend of remote staff, field-based clinical personnel, or smaller satellite offices that extend the company’s reach beyond its primary hubs.
